midas716, The 100 Million Shares Acquired Explained...
First, it's Sterling and not Steve. People sometimes get my codename stervc mixed up with my name and read it as steve.
Second, neither you nor I am the gospel as for what we believe or say. Of course the .001 per share for the 100,000,000 shares could just be a typo, but I don't think so. The Form 4 says "100,000,000" Shares "ACQUIRED" which means that he did not "give" them to himself for free as it seems like you keep twisting that fact trying to make others to believe. I believe this is a "transaction" representing an exchange as payment for the Greater Cannabis Company, Inc. (GCAN) public entity. This means that we have our merger candidate and to standby to see just how big it is!
Just so you know... again... per the GCAN Form 4 filed with the SEC below by GCAN CEO Aitan Zacharin:
After going back to read the Form 4, here is what I think it is saying. These words "acquired" and "deferred compensation" means that some kind of a "transaction" has taken place in the form of a "payment" and not the CEO giving himself free shares. You keep saying that he bought them, but because he only paid $10,000 for the 100 Million shares, that means that he only paid .0001 per share for the shares and that he stole them. I believe that is wrong to say and is very incorrect based on what's in the Form 4. That's where the words "deferred payment" comes in. Read the definition below for deferred payment below:
So, from how things appear, it looks like... deferred compensation "owed" Aitan Zacharin by the "Issuer." ...means that Aitan Zacharin has owed to him the balance of $90,000 at a "deferred" time or later time in the future as agreed upon by all key parties involved since he is getting 100 Million common shares at .001 per share to be included with a payment of $10,000. That's a total of $100,000 for the shares which is where the .001 per share comes from since 100,000,000 x .001 per share = $100,000. The "Issuer" is GCAN which the way it's used within the Form 4 leads me to believe that there is a new "Issuer" as it is not Aitan Zacharin anymore. I think it's a great deal for everyone because it confirms that a new company has been selected to be coming into GCAN and has already taken over. So it's not stealing as you have been trying to convince investors to believe. There is nothing pessimistic about this. This is actually very optimistic for a few reasons that I'm guessing I don't need to explain un greater detail. Bottom line, this now positions the company for a huge merger to come into GCAN as it looks like it is already happening administratively behind the scenes! This had to be done.
Now, because of the GCAN current CEO's resume, Aitan Zacharin, I believe something very big will be merging into GCAN:
Mr. Zacharin is an experienced executive with broad knowledge in building and managing technology, biopharmaceutical, healthcare and consumer products businesses. Mr. Zacharin has founded a number of companies, and has seen them through successful listings in the public markets, with collective valuations of over $1 billion. Mr. Zacharin has been advising and investing in early to mid-stage startups, and assisting them with development, capitalization, accelerating growth, and turnaround strategies. He specializes in strategic acquisitions, structuring complex transactions, reverse mergers, and brings domestic and international experience in operations, accounting, audit preparation, due diligence, capital raising and restructuring, debt financing, and mergers and acquisitions. In 2012 he co-founded Fuse Science, an innovative biotechnology company and was responsible for growth of the business from its conceptual stage to a publicly traded CPG and biotech business with multiple subsidiaries. He structured pivotal deals with key partners, which led to the company successfully raising over $20 million to commercialize its products, including brand ambassador agreements with 26 sports celebrities, including world renowned athlete Tiger Woods. He successfully exited from the company, which had reached a $110 million valuation. In 2014, Mr. Zacharin was appointed to the Board of Directors for Mediconecta, the largest telehealth Company in Latin America serving millions of patients with on-demand, high quality healthcare. Within six months, Mr. Zacharin facilitated and negotiated an eight figure buyout offer from Teladoc (NASDAQ: TDOC), the world’s largest telehealth company, just prior to its IPO. In 2015, Mr. Zacharin became the managing partner of Secure Hosting LLC, a blockchain mining company with a co-location mining farm in North Carolina. After two years of scaling out the operations to nearly $15,000,000 in assets, he successfully structured the sale of the company to a leading publicly traded blockchain mining company. In 2017, Mr. Zacharin founded GCANRx (OTC: GCAN), a publicly traded biopharmaceutical company focused on repurposing a highly bioavailable transmucosal drug delivery system that had previously been commercialized in partnership with Novartis. Mr. Zacharin repurposed the platform technology for use in cannabinoid therapeutics. He then negotiated a worldwide exclusive license from Shaare Zedek Scientific, the licensing arm of one of Israel’s largest research hospitals, for a cannabinoid-based therapeutic used in treating neuropsychiatric disorders. The therapeutic was invented by world-renowned cannabis researcher, Dr. Adi Aran, M.D. The Company is currently in the final stages of regulatory approval for a 100 patient Phase 2 clinical study for the treatment of autism related spectrum disorders. In 2018, Mr. Zacharin became a shareholder in sports technology company, Slinger (NASDAQ: CNXA). The company manufactures an innovative, patented sports product called the Slinger Bag, which raised $1 million through a highly successful Kickstarter campaign. Mr. Zacharin was tasked by the founder to take the company public. The Company was led by the past- CEO of global tennis company Prince. Within the first 18 months of operations the company grew to a global footprint of 65 countries, signed $250 million in distribution agreements, and achieved a market cap of over $400 million. Throughout the growth of the company, Mr. Zacharin served as the head of investor relations and was instrumental in raising the company over $27 million from leading Wall Street investors, and overseeing the IR strategy, which led to the stock rising over 1,700% from its listing price. Mr. Zacharin was actively involved in Slinger’s acquisition of three companies, most notably a Softbank and Verizon Ventures backed artificial intelligence sports company for $100 million. Mr. Zacharin led the effort of putting together a team, which successfully uplisted the Company from the OTC Markets to the Nasdaq. In 2019, Mr. Zacharin joined an investor group who acquired Solstice Sunglasses, the second largest sunglasses retailer in the US, to list the company’s shares on the public markets. Mr. Zacharin led the merger of Solstice with a public vehicle, which enabled a multi-million dollar round of financing for the retailer. In 2020, Mr. Zacharin identified, structured and facilitated the acquisition of a luxury, multi-state substance abuse facility. Mr. Zacharin secured financing for the $18 million acquisition with a combination of investments from high net worth individuals and a loan facility from a speciality banking lender. The company subsequently purchased two additional drug rehab portfolios, and grew to become a leading multi-state operator in the drug rehabilitation industry. In 2021, Mr. Zacharin became the co-founder and CEO of PlasmaCure, a groundbreaking medical device company focused on R&D and commercialization of an oncology treatment licensed from GW University. Mr. Zacharin holds dual degrees from the University of South Florida. He serves in an executive capacity to two publicly listed companies, and maintains various board non-profit board appointments.
AI
